XML 35 R21.htm IDEA: XBRL DOCUMENT
v3.20.4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Accounting Policies [Abstract] |
Schedule of Service Fee Revenue | Our total net revenues for the years ended December 31, 2020, 2019, and 2018 are presented in the table below (in thousands):
| 2020 |  | 2019 |  | 2018
Commercial insurance | $ | 584,035 |  |  | $ | 642,341 |  |  | $ | 542,011 |
Medicare | 217,928 |  |  | 237,427 |  |  | 192,881 |
Medicaid | 25,619 |  |  | 28,283 |  |  | 25,615 |
Workers' compensation/personal injury | 33,478 |  |  | 42,792 |  |  | 34,193 |
Other patient revenue | 25,314 |  |  | 23,862 |  |  | 25,117 |
Management fee revenue | 11,253 |  |  | 11,659 |  |  | 13,882 |
Imaging on call and software | 10,798 |  |  | 17,317 |  |  | 16,261 |
Other | 23,297 |  |  | 24,555 |  |  | 18,781 |
Service fee revenue | 931,722 |  |  | 1,028,236 |  |  | 868,741 |
Revenue under capitation arrangements | 140,118 |  |  | 125,943 |  |  | 106,405 |
Total revenue | $ | 1,071,840 |  |  | $ | 1,154,179 |  |  | $ | 975,146 |
Schedule of Effect of Derivative Instruments on Comprehensive Income | A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive (loss) income, net of taxes is as follows (amounts in thousands):
| Interest Rate Contracts |
For the twelve months ended | Amount of Gain (Loss) Recognized on Derivative, net of taxes | Location of Gain (Loss) Recognized in Income on Derivative
December 31, 2020 | $788 | Other Comprehensive Income
December 31, 2019 | (4,383) | Other Comprehensive Loss
December 31, 2018 | 2,876 | Other Comprehensive Income
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):
Interest Rate Contracts - Effective Portion
For the twelve months ended | Amount of Loss Recognized on Derivative, net of taxes | Location of Loss Recognized in Income on Derivative
December 31, 2020 | $(20,160) | Other Comprehensive Loss
December 31, 2019 | $(5,870) | Other Comprehensive Loss
A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective in 2020 is as follows (amounts in thousands):
Interest Rate Contracts - Ineffective Portion
For the twelve months ended | Amount of loss recognized in income on derivative (current period ineffective portion) | Location of loss recognized in Income on derivative (current period ineffective portion) | Amount of loss reclassified from accumulated OCI into income (prior period effective portion) | Location of loss reclassified from accumulated OCI into income (prior period effective portion)
December 31, 2020 | $(2,528) | Other Income (Expense) | $(3,448) | Equity and Interest Expense
Schedule of Fair Value of Assets and Liabilities | The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands):
| As of December 31, 2020
| Level 1 |  | Level 2 |  | Level 3 |  | Total
Current and long term liabilities |  |  |  |  |  |  |
2016 CAPS - Interest Rate Contracts | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
2019 SWAPS - Interest Rate Contracts | $ | — |  |  | $ | 37,989 |  |  | $ | — |  |  | $ | 37,989 |
| As of December 31, 2019
| Level 1 |  | Level 2 |  | Level 3 |  | Total
Current and long term liabilities |  |  |  |  |  |  |
2016 CAPS - Interest Rate Contracts | $ | — |  |  | $ | 1,081 |  |  | $ | — |  |  | $ | 1,081 |
2019 SWAPS - Interest Rate Contracts | $ | — |  |  | $ | 9,477 |  |  | $ | — |  |  | $ | 9,477 |
The table below summarizes the estimated fair value and carrying amount of our SunTrust (Term Loan Agreement) and Barclays (First Lien Term Loans) long-term debt as follows (in thousands):
| As of December 31, 2020
| Level 1 |  | Level 2 |  | Level 3 |  | Total Fair Value |  | Total Face Value
Term Loan Agreement and First Lien Term Loans | $ | — |  |  | $ | 661,640 |  |  | $ | — |  |  | $ | 661,640 |  |  | $ | 662,403 |
| As of December 31, 2019
| Level 1 |  | Level 2 |  | Level 3 |  | Total Fair Value |  | Total Face Value
Term Loan Agreement and First Lien Term Loans | $ | — |  |  | $ | 708,948 |  |  | $ | — |  |  | $ | 708,948 |  |  | $ | 705,699 |
Schedule of Earnings Per Share | Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
| Years Ended December 31,
| 2020 |  | 2019 |  | 2018
Net (loss) income attributable to RadNet, Inc. common stockholders | $ | (14,840) |  |  | $ | 14,756 |  |  | $ | 32,243 |
BASIC NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS |  |  |  |  |
Weighted average number of common shares outstanding during the period | 50,891,791 |  |  | 49,674,858 |  |  | 48,114,275 |
Basic net (loss) income per share attributable to RadNet, Inc. common stockholders | $ | (0.29) |  |  | $ | 0.30 |  |  | $ | 0.67 |
DILUTED NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS |  |  |  |  |
Weighted average number of common shares outstanding during the period | 50,891,791 |  |  | 49,674,858 |  |  | 48,114,275 |
Add nonvested restricted stock subject only to service vesting | — |  |  | 208,963 |  |  | 180,631 |
Add additional shares issuable upon exercise of stock options and warrants | — |  |  | 360,185 |  |  | 384,093 |
Weighted average number of common shares used in calculating diluted net income per share | 50,891,791 |  |  | 50,244,006 |  |  | 48,678,999 |
Diluted net (loss) income per share attributable to RadNet, Inc. common stockholders | $ | (0.29) |  |  | $ | 0.29 |  |  | $ | 0.66 |
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive: |  |  |  |  |
Nonvested restricted stock subject to service vesting | 329,159 |  |  | — |  |  | — |
Shares issuable upon the exercise of stock options | 554,444 |  |  | — |  |  | — |
Schedule of Investment in Joint Ventures | The following table is a summary of our investment in joint ventures during the years ended December 31, 2020 and December 31, 2019 (in thousands):
Balance as of December 31, 2018 | $ | 37,973 |
Equity contributions in existing and purchase of interest in joint ventures | 103 |
Equity in earnings in these joint ventures | 8,350 |
Sale of ownership interest | (134) |
Dissolution of GSRN | (1,428) |
Nulogix return of capital | (792) |
Nulogix change in control | (1,004) |
Distribution of earnings | (8,598) |
Balance as of December 31, 2019 | $ | 34,470 |
Equity contributions in existing and purchase of interest in joint ventures | 1,635 |
Equity in earnings in these joint ventures | 7,945 |
Distribution of earnings | (9,522) |
Balance as of December 31, 2020 | $ | 34,528 |
Joint Venture Investment and Financial Information | The following table is a summary of key unaudited financial data for these joint ventures as of December 31, 2020 and 2019, respectively, and for the years ended December 31, 2020, 2019 and 2018, respectively, (in thousands):
| December 31,
Balance Sheet Data: | December 31, 2020 |  | 2019
Current assets | $ | 27,085 |  |  | $ | 27,427 |
Noncurrent assets | 68,686 |  |  | 61,037 |
Current liabilities | (12,545) |  |  | (9,217) |
Noncurrent liabilities | (21,582) |  |  | (18,872) |
Total net assets | $ | 61,644 |  |  | $ | 60,375 |
Book value of RadNet joint venture interests | $ | 28,079 |  |  | $ | 28,001 |
Cost in excess of book value of acquired joint venture interests accounted for as equity method goodwill | 6,449 |  |  | 6,469 |
Total value of RadNet joint venture interests | $ | 34,528 |  |  | $ | 34,470 |
| 2020 |  | 2019 |  | 2018
Net revenue | $ | 101,921 |  |  | $ | 108,051 |  |  | $ | 155,820 |
Net income | $ | 16,850 |  |  | $ | 18,624 |  |  | $ | 24,596 |

X
- Definition Joint venture investment and financial information + References No definition available. + Details
Name: | rdnt_JointVentureInvestmentAndFinancialInformationTableTextBlock
Namespace Prefix: | rdnt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueByBalanceSheetGroupingTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959 + Details
Name: | us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 940 -SubTopic 320 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=35711157&loc=d3e42567-110969 + Details
Name: | us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration